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Atrial fibrillation (AF) in hypertrophic cardiomyopathy (HC) is associated with significant 
symptomatic deterioration, heart failure and thromboembolic disease. There is a need for 
better mechanistic insight and improved identification of at risk patients.: We used CMR to 
assess predictors of AF in HC, in particular the role of myocardial fibrosis. Consecutive 
patients with HC referred for CMR 2003-2013 were prospectively enrolled. CMR parameters 
including left ventricular volumes, presence and percentage of late gadolinium enhancement 
in the left ventricle (%LGE) and left atrial volume index (LAVi) were measured.   Overall, 
377 patients were recruited (age 62 ±14 years, 73% men). Sixty-two patients (16%) 
developed new-onset AF during a median follow up of 4.5 (IQR 2.9 - 6.0) years. 
Multivariable analysis revealed %LGE [hazard ratio (HR) 1.3 per 10% (CI: 1.0-1.5; p=0.02), 
LAVi [HR 1.4 per 10mL/m2 (1.2-1.5; p<0.001)], age at HC diagnosis, non-sustained 
ventricular tachycardia and diabetes to be independent predictors of AF. We constructed a 
simple risk prediction score for future AF based on the multivariable model with a Harrell’s 
C-statistic of 0.73.   In conclusion, the extent of ventricular fibrosis and LA volume 
independently predicted AF in patients with HC. This finding suggests a mechanistic relation 
between fibrosis and future AF in HC. CMR with quantification of fibrosis has incremental 
value over LV and LA measurements in risk stratification for AF.  A risk prediction score 
may be used to identify patients at high risk of future AF who may benefit from more 
intensive rhythm monitoring and a lower threshold for oral anticoagulation. 
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Patients with hypertrophic cardiomyopathy (HC) have a 10-fold risk of developing atrial 
fibrillation (AF) compared to the general population1,2 and these patients have a high risk of 
stroke3 and heart failure3–5. Our current practice is periodic ambulatory ECG monitoring and 
monitoring of symptoms, however stroke may be the first clinical presentation of AF. 
Identifying patients at risk of AF would allow more targeted, personalized treatment and 
more judicious use of continuous ambulatory monitoring.  There are a number of potential 
contributory structural factors that may lead to development of AF, including left atrial 
dilatation6, atrial myocardial fibrosis7,8 and myocardial ischaemia9.  However, the value of 
these parameters in predicting development of AF in HC remains unclear. Cardiovascular 
magnetic resonance (CMR) allows quantification of fibrosis burden, accurate ventricular and 
atrial volume measurement and detection of myocardial ischemia10.  Accordingly, we aimed 
to assess the prognostic value of CMR parameters to predict the development of AF in HC. 
Methods 
From December 2003 to April 2013, consecutive patients referred with a diagnosis of 
known or suspected HC underwent a CMR scan including myocardial perfusion and late 
gadolinium enhancement at the Royal Brompton Hospital in London UK. All patients met the 
American College of Cardiology Foundation/American Heart Association (ACCF/AHA) 
diagnostic criteria for HC11. Exclusion criteria were previous or current AF, metabolic 
diseases resulting in HC phenocopies such as Anderson-Fabry disease, significant primary 
valvular disease (excluding mitral regurgitation secondary to systolic anterior motion of the 
mitral valve), patients with contra-indication to CMR study including presence of an 
implantable cardioverter defibrillator (ICD) or pacemaker and patients with severe untreated 
hypertension. The study was approved by the Institutional Ethics Committee.  Written 
informed consent was obtained from all study patients.  





 CMR imaging was performed on a 1.5 T clinical scanner (Siemens Sonata/Avanto, 
Erlangen, Germany.  Anatomic imaging was performed using Half-Fourier Acquisition 
Single-shot Turbo spin Echo (HASTE) sequences and steady-state free precession sequences 
were used to obtain cine images in standard two-, three- and four-chamber long axis views, 
with subsequent contiguous short-axis cines from the mitral annulus to the apex of the heart.   
The left atrium was assessed in two and four chamber long axis views. 
 Late gadolinium enhancement (LGE) images were acquired 10 minutes after the 
administration of intravenous gadolinium contrast agent (Gadovist or Magnevist, Bayer-
Schering, Berlin, Germany, 0.1mmol/kg) in both long- and short- axes with a breath-hold 
inversion-recovery gradient echo sequence. The inversion time was adjusted to ensure 
adequately nulled myocardium and images were obtained in two orthogonal phase-encoding 
directions to allow exclusion of artefact.  
 Myocardial first-pass perfusion imaging was performed using a saturation-recovery 
prepared dual-sequence approach with center-out hybrid echoplanar imaging (EPI) using the 
following typical sequence parameters: fat saturation pulse, composite 90° saturation 
preparation pulse for each slice, 28° readout pulse, repetition time 5.1 ms, echo time 1.1 ms, 
echo train length 4, field of view 360 × 288 mm, base resolution 160 × 160, slice thickness 8 
mm. Three short axis images were acquired every cardiac cycle for a total of 30 cycles at 
peak adenosine hyperemia.  Adenosine was infused at 140 mcg/kg/min for 4 minutes and 
symptoms, heart rate and blood pressure were monitored.  At peak hyperemia, a bolus of 
gadolinium contrast (Magnovist or Gadovist, Bayer-Schering, Berlin, Germany, 0.1 
mmol/kg) was rapidly injected, followed by a saline bolus.   
 A commercially available program (CMR Tools, Cardiovascular Imaging Solutions, 
London) was used to measure left ventricular volumes, stroke volume and ejection fraction.  
Left atrial (LA) area and length were carefully measured in two- and four-chamber views at 





end ventricular systole. The LA area was measured by tracing the atrial endocardial border, 
excluding the pulmonary veins, LA appendage and mitral recess and the LA volume was then 
calculated using the biplane area-length method12 and indexed to body surface area (LAVi).   
 Ventricular LGE was quantified using the “full width half maximum” method13 using 
dedicated imaging software (CMR42, Circle Cardiovascular Imaging, Calgary, Canada) and 
presented as a percentage of total LV mass (%LGE). All analyses were performed by 
experienced operators blinded to patient outcome.   
 An inducible perfusion defect was reported to be present if hypointense signals were 
demonstrated in the subendocardial or transmural regions of the LV wall, persisting for three 
or more frames from when contrast is first visualized in the LV myocardium on stress images 
but not in concurrent rest images. Papillary muscles were not included in the perfusion 
assessment. A summed difference score (SDS)14,15 utilizing the ACC/AHA 17-segment 
model16 but excluding the cardiac apex, was used. The following scores were used to rate 
each segment at rest and stress: 0 – no defect, 1 – inducible perfusion defect <50% of wall 
thickness, 2 – inducible perfusion defect >50% of wall thickness.  The SDS was derived by 
subtracting the rest score from the stress score.   
 The endpoint was defined as a new diagnosis of AF, either paroxysmal or persistent. 
Paroxysmal AF was defined as AF that terminated within 7 days and persistent AF was 
defined as AF that lasted longer than 7 days. AF was considered to be present if a diagnosis 
of new AF was documented in the patient record or an ECG demonstrating AF was recorded. 
Where a cardiac implantable electronic device was used to diagnose AF, a minimum duration 
of >30s was used for the diagnosis.  Where the presence of AF was in doubt due to unclear 
documentation (e.g. documentation of “possible AF on Holter monitor”), original ECG 
records were obtained and if necessary, an independent cardiologist was enlisted as a final 
adjudicator.  Ambulatory ECG monitoring during follow-up was performed at the 





cardiologist’s discretion.  The majority of patients had a yearly Holter monitor.   
 Patients’ vital statuses (alive/dead) were checked at six-monthly intervals via the UK 
National Strategic Tracing Service. Patients were followed up via a combination of telephone 
and postal questionnaires as well as review of medical records from primary and secondary 
care at 6-month intervals. The received data was assessed by a clinician for documentation of 
any AF events. 
 Baseline characteristics are presented as frequency (%) for categorical data and mean 
± standard deviation (SD) or median (IQR) for continuous data as appropriate. Baseline 
variables were compared between groups using Fisher’s exact test for categorical variables 
and Mann-Whitney U test for continuous variables.  Kaplan-Meier survival curves were 
generated and compared using the log-rank test.  Univariable Cox proportional hazards 
models were used to test the association between baseline covariates and subsequent AF.  
Results were presented as hazard ratios and 95% confidence intervals.  A multivariable risk 
prediction model was built using a forward stepwise selection procedure.  A p-value <0.05 
was considered significant. Harrell’s C statistic was used to determine LAVi, %LGE and age 
at diagnosis cut-off points that provided the best discrimination between the AF and no AF 
populations and Kaplan-Meier curves were generated using these cut-off points. A risk score 
was generated using the coefficients from the multivariable Cox model.   Missing data was 
dealt with using multiple imputation by chained equations. The imputation models included 
the primary outcome, the Nelson-Aalen estimator of the cumulative hazard function and 
baseline variables with no missing data. Ten imputation sets were generated and mean values 
averaged over these sets were imputed for the model selection process. The coefficients of 
the risk prediction model were estimated by averaging over the 10 imputations using Rubin’s 
rule17.   Statistical analysis was performed using Stata 15.   
Results 





A total of 377 patients (mean age 62 ±14, 73% male) were recruited.  Exclusions were 
prior or current AF (n=18, 5%), inadequate baseline data (n=5, 1%) and patients lost to 
follow up (n=6, 2%), giving a final population of 348 patients (Figure 1, Table 1).   
 The median follow-up period was 4.5 years (2.9, 6.0) with a total of 1532 patient-
years of follow-up. During follow-up, sixty-two patients (16%) developed new AF. The 
incidence of AF was 4.0 (CI: 3.2-5.2) per 100 person-years. There were 22 deaths during 
follow-up including 1 stroke death, 6 heart failure deaths and 2 sudden cardiac deaths. Six 
patients (2%) had an ischemic stroke during follow-up, none of whom had AF at baseline. 
Two were subsequently diagnosed with AF during workup for stroke.   
This was a real-world study design and no follow-up strategy for AF detection was 
prespecified across the cohort.  The majority of patients underwent yearly annual ambulatory 
ECG monitoring.  Two subsets had standardized follow-up: patients under follow-up at the 
Royal Brompton Hospital, who underwent regular annualized ambulatory ECG monitoring 
(53 patients, 15%), and those with subsequently implanted devices (48 patients with ICD or 
pacemaker (14%)). New AF was diagnosed in 14 (26%) Brompton patients and 14 (29%) 
patients with ICD/pacemaker. In the rest of the cohort, 36 (15%) had new AF. Neither subset 
were found to be predictive of AF on univariable analysis (p = 0.35 and p = 0.90, 
respectively), however the study was not powered to assess this. 
Univariable and multivariable analyses for predictors of AF are shown in Table 2.  
.LAVi and %LV LGE were independently predictive of AF.  The range of LAVi and %LV 
LGE and their corresponding hazard ratios and estimated 5-year event rates are described in 
Table 3 and Figure 2 respectively.  Example CMR images are shown in Figure 4.  The cut-off 
points for %LGE and LAVi which maximized discrimination of the multivariable risk 
prediction model were found to be 16% and 52mL/m2 respectively. These were used to 
generate Kaplan-Meier curves (Figure 3). Example CMR images are shown in Figure 4.  At 5 





years, patients with LGE >16% were more than twice as likely to develop AF compared to 
LGE≤16% (23% vs. 12%; p=0.005, Figure 3a) and patients with LAVi >52mL/m2 were more 
than three times as likely to develop AF compared to LAVi≤52 mL/m2 (25% vs. 8%; 
p<0.0001, Figure 3b).   Based on the multivariable model the five-year risk of development 
of AF can be predicted as follows: 
         5 Year Risk = 1- 0.997e(RS) 
Where RS= [0.030×LAVi]+[0.023×%LGE]+[age at diagnosis of HC×0.031] + 
[0.679 (if NSVT)]+[0.918 (if Diabetic)] 
(RS= risk score, e=exponential function) 
The Harrell’s C Statistic for this model was 0.73. 
A simplified risk score model was constructed by dividing the population into low-
risk, medium-risk and high-risk groups based on the five factors predicting AF on 
multivariable analysis. Patients were considered low risk if they had 0 or 1 risk factor, 
medium risk if they had 2 factors and high risk if they had 3 or more risk factors.  A score of 
1 was given for each of the following: LGE>16%, LAVi>52mL/m2, diabetes, presence of 
NSVT and age at diagnosis >53 years. Figure 3(c) shows the cumulative incidence of AF 
stratified by risk-group. The HR for developing AF for the medium- and high-risk groups 
compared to the low risk group were 4.9 (CI: 2.1-11.2) and 12.6 (5.5-29.0) respectively. The 
Harrell’s C Statistic for the simplified model was 0.73, demonstrating similar power of 
discrimination to the full risk model.  
  






Patients with HC who develop AF are known to be at increased risk for heart failure 
and thromboembolic events, including stroke.  We demonstrated that the extent of myocardial 
fibrosis and LA volume determined by CMR were strong independent predictors of AF. Our 
results suggest that myocardial replacement fibrosis may have a mechanistic role in 
development of AF.  We formulated a risk prediction that may be used to identify high risk 
patients. Compared to those with minimal or no LGE and LAVi 40mL/m2, patients with 
moderate %LGE (10%) and LAVi 60mL/m2 were more than twice as likely to develop AF 
whereas patients with extensive %LGE (40%) and a LAVi of ≥ 80ml/m2 had more than an 8-
fold risk of developing AF during follow-up.   CMR allows identification of high-risk 
patients who may benefit from more intensive follow up, perhaps with wearable digital 
ambulatory devices, and in whom there should be a low threshold for oral anticoagulation.  
 Our data suggest a potential causal relationship between %LGE and AF in HC.  Other 
variables closely linked to HC disease severity such as maximum wall thickness, LV 
volumes, resting LV outflow tract gradient and LV ejection fraction were not significant 
predictors of AF, suggesting that the relationship between AF and %LGE is unlikely to 
simply reflect an increased prevalence of AF in more severe disease. Anti-fibrotic therapies 
may therefore reduce the incidence of new AF in HC. 
 The initiation and maintenance of AF is complex (Figure 5).  LV fibrosis may lead to 
increased  LV filling pressures and a chronically increased  LA pressure, leading to LA 
dilatation18.   Fibrosis within the left atrial wall may additionally interfere with local atrial 
conduction19–21. We found that ventricular LGE remained a significant predictor of AF 
following adjustment for LA volume, suggesting that LA stretch alone does not fully explain 
the development of AF. Measurement of LA fibrosis is challenging due to the thin-walled left 
atrium, partial volume effects and artefact22, although recent efforts to produce accurate and 





reproducible LA fibrosis measurements have been promising23,24 . While it was not possible 
to assess the amount of atrial fibrosis directly in this study, we would suggest that patients 
with extensive ventricular fibrosis are likely to also have a greater degree of atrial fibrosis 21.  
However, ventricular fibrosis may act as a marker of more severe or progressive HC leading 
to increased risk of AF rather than a causal relationship25.  
 In contrast to previous work6,8, we found LA volume and LGE to be independently 
predictive of AF. This is likely due to the greater number of events in our cohort, however we 
also employed different methods for quantification of LGE (full width half maximum rather 
than 6SD)13.  To our knowledge, this is the largest study to date demonstrating the extent of 
LV LGE to be an independent predictor of AF in HC8,26.   In keeping with previous work, we 
demonstrated LAVi1 and diabetes27,28 to be independent predictors of AF.  We extended this 
work to formulate a risk prediction model that could easily be employed in day-to-day 
clinical practice to identify high-risk patients.   
 We would suggest that frequent use of ambulatory ECG monitoring or patient 
activated event monitoring may be of benefit in patients with a severely dilated LA and 
extensive LGE who are currently in sinus rhythm.  Wearable electronic devices capable of 
ECG provide an opportunity for continuous monitoring without implantation of loop 
recorders and may be the modality of choice going forward, although the sensitivity of these 
devices in capturing AF is outside the scope of our study.  Patients at high risk may even 
benefit from prophylactic anticoagulation, although this requires formal evaluation on a 
risk/benefit basis.  Interestingly, patients who went on to develop AF had a higher prevalence 
of beta blocker use at baseline than those who did not develop AF (68% vs 52%, p=0.02), 
suggesting that beta blockers may not be effective at preventing future AF in HC, although 
this cannot be concluded from observational data. 
 Study Limitations: This was a single-center study in a tertiary referral center for CMR 





and may therefore be subject to referral bias. This was partly mitigated since referrals were 
from a broad source including our cardiomyopathy clinical service and a network of referring 
hospitals.  As CMR was used in this study, patients with more advanced disease may have 
been excluded due to presence of an ICD or pacemaker. The mean age of our cohort was 
62±14 years and our cohort may therefore reflect more established disease.  Our findings and 
risk score will need to be validated in other cohorts. 
 Patients did not have continuous ECG monitoring, nor was frequency of monitoring 
standardized. Episodes of asymptomatic paroxysmal AF would not have been captured and 
the true prevalence of AF in our cohort is therefore likely underestimated. Similarly, the 5-
year risk of AF as predicted by our model may be an underestimate. However, this is 
representative of real-world practice and is in keeping with the methodology of previous 
studies. Importantly, any decisions on management are likely to be based on a similar level of 
monitoring.  We did not find a difference in rates of AF in patients followed up at our 
institution (where yearly 24h ECG monitors were routinely performed) or those with devices 
capable of continuous rhythm recording compared to the remainder of the population.  T1 
mapping was not available at the outset of the study and therefore not performed.  Our 
sequences were not optimized for pulmonary vein assessment so pulmonary vein morphology 
was not assessed.   
 In conclusion, both LA volume and %LGE had independent prognostic value in 
prediction of AF in HC.  This suggests a potential mechanistic role for myocardial fibrosis in 
the development of AF in HC.  In addition to risk stratification for sudden cardiac death, 
CMR allows identification of patients at high risk of future AF, allowing closer clinical 
follow-up and monitoring with the potential to introduce prophylactic anticoagulation therapy 
in those at highest risk. 
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Figure and Table Legends 
 
Figure 1: Consort chart describing patient recruitment  
Figure 2: Left atrial volume and LGE had independent prognostic values.  5-year Kaplan-
Meier event rates for varying combinations of %LGE and LAVi are displayed graphically. 
Figure 3: Kaplan-Meier graphs comparing AF cumulative incidence between (a) 
%LGE≤16% and %LGE >16%, (b) LAVi≤52 mL/m2 and LAVi >52mL/m2 groups and (c) 
low-risk (≤1 RF), medium-risk (2 RF) and high-risk (≥3 RF)groups based on the number risk 
factors (RF) with a score of 1 given for each of the following: LGE>16%, LAVi>52mL/m2, 
diabetes, presence of NSVT and age at diagnosis >53 years, (d) LGE≤16% and 
LAVi≤52ml/m2 vs LGE>16% and LAVi>52ml/m2.  Four patients did not have LGE 
quantification due to poor image quality. 
Figure 4: Example CMR images.  Measurement of the left atrium was performed in 2- and 4- 
chamber views at end systole as described in panels A and B.  Panels C and E show short axis 
LGE images of a low risk patient with no LGE enhancement.  Panels D and F show a high 
risk patient with extensive LGE (arrowed) who went on to develop AF. 
Figure 5 - Central illustration: Coumel’s triangle adapted for HCM.  The triangle describes 
the triggers, substrate and modulating factors that lead to atrial fibrillation.  Risk factors 
found to be predictive of AF in our study are marked in bold and with an asterisk.  Risk 
factors that have been previously described in AF in the general cardiology population but 
were not predictive in this study are in italics and marked with an obelisk (†).   
 
Table 1: Baseline characteristics  
Table 2: Univariable and multivariable analyses of AF predictors.  *NSVT was not 
significant on univariable analysis as its presence was associated with younger age and less 





diabetes (which are protective factors for future AF).  When entered in a multivariable model 
with these factors, it is unmasked as a significant predictor of future AF.    
HR = Hazard ratio; CI = Confidence interval 
Table 3: Hazard ratios (HR) and 95% confidence intervals for varying combinations of 
%LGE and LAVi compared to absent LGE and LAVi 40 mL/m2. 
Numbers are presented as HR (95% confidence interval) 
 
